DOK1, docking protein 1, 1796

N. diseases: 45; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.010 Biomarker disease BEFREE Furthermore, because pp60(c-src) and pp62(c-yes) appear redundant to the growth regulation of normal colonic epithelial cells, the data suggest that src-specific inhibitors might be of therapeutic value for colon cancer. 9056668 1997
CUI: C0009375
Disease: Colonic Neoplasms
Colonic Neoplasms 		0.010 Biomarker group BEFREE The vector was transfected into HT 29 cells, an established colon tumor cell line in which both pp60(c-src) and pp62(c-yes) are activated. 9056668 1997
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 Biomarker disease BEFREE Furthermore, because pp60(c-src) and pp62(c-yes) appear redundant to the growth regulation of normal colonic epithelial cells, the data suggest that src-specific inhibitors might be of therapeutic value for colon cancer. 9056668 1997
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.010 AlteredExpression disease BEFREE In terms of the comparison between non-endometriosis and endometriosis group, the mRNA levels of AhR, Arnt, CYP1B1 and p62(dok) were essentially similar. 10724351 1999
CUI: C0549463
Disease: X-Linked Lymphoproliferative Disorder
X-Linked Lymphoproliferative Disorder 		0.010 Biomarker disease BEFREE An SH2D1A SH2 domain mutant that has been identified in XLP does not associate with Dok1, in accord with the hypothesis that this interaction is linked to XLP. 10852966 2000
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.030 Biomarker disease BEFREE These data indicate that p62(dok) acts as a negative regulator of growth factor-induced cell proliferation, at least in part through downregulating Ras/MAPK signaling pathway, and that p62(dok) can oppose leukemogenesis by p210(bcr-abl). 11489947 2001
CUI: C0023473
Disease: Myeloid Leukemia, Chronic
Myeloid Leukemia, Chronic 		0.010 Biomarker disease BEFREE p62(dok) has been identified as a substrate of many oncogenic tyrosine kinases such as the chronic myelogenous leukemia (CML) chimeric p210(bcr-abl) oncoprotein. 11489947 2001
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.010 AlteredExpression group BEFREE Furthermore, p62(dok) inactivation causes a significant shortening in the latency of the fatal myeloproliferative disease induced by retroviral-mediated transduction of p210(bcr-abl) in bone marrow cells. 11489947 2001
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.030 Biomarker disease BEFREE This is the first example of a Dok1 mutation in B-CLL and the data suggest that Dok1 might play a role in leukemogenesis. 14730347 2004
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.020 GeneticVariation disease BEFREE We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis. 14730347 2004
CUI: C1868683
Disease: B-CELL MALIGNANCY, LOW-GRADE
B-CELL MALIGNANCY, LOW-GRADE 		0.010 GeneticVariation disease BEFREE We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis. 14730347 2004
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.020 GeneticVariation disease BEFREE Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia. 15541476 2005
CUI: C1611743
Disease: Familial (FPAH)
Familial (FPAH) 		0.010 GeneticVariation disease BEFREE To examine the proposition that germline mutations in Dok1 act as high penetrance susceptibility alleles for CLL we screened 140 familial cases for functional sequence variants.No pathogenic mutations were detected. 15541476 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Dok1 is an adaptor tyrosine kinase substrate with tumor-suppressive activity. 16338067 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.060 AlteredExpression group BEFREE Our data show that Dok1 expression and structure are affected in a subset of Burkitt's lymphoma samples, suggesting its possible role in this type of cancer. 16338067 2007
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.040 AlteredExpression group BEFREE Our data show that Dok1 expression and structure are affected in a subset of Burkitt's lymphoma samples, suggesting its possible role in this type of cancer. 16338067 2007
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma 		0.020 AlteredExpression disease BEFREE Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells. 16338067 2007
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma 		0.020 AlteredExpression disease LHGDN Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells. 16338067 2007
CUI: C0278764
Disease: Adult Burkitt Lymphoma
Adult Burkitt Lymphoma 		0.020 AlteredExpression disease BEFREE Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells. 16338067 2007
CUI: C0278879
Disease: Childhood Burkitt Lymphoma
Childhood Burkitt Lymphoma 		0.020 AlteredExpression disease BEFREE Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells. 16338067 2007
CUI: C0023418
Disease: leukemia
leukemia 		0.050 AlteredExpression disease BEFREE The data in this report show that both the DOK1 and the DOK2 adaptor proteins are constitutively expressed in the myelomonoblastic leukemia cell line, HL-60, and that expression of both proteins is induced by the chemotherapeutic differentiation causing agents, all-trans retinoic acid (atRA) and 1,25-dihydroxyvitamin D3 (VD3). 16823827 2006
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.040 AlteredExpression disease BEFREE The data in this report show that both the DOK1 and the DOK2 adaptor proteins are constitutively expressed in the myelomonoblastic leukemia cell line, HL-60, and that expression of both proteins is induced by the chemotherapeutic differentiation causing agents, all-trans retinoic acid (atRA) and 1,25-dihydroxyvitamin D3 (VD3). 16823827 2006
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.030 Biomarker disease BEFREE Originally identified in chronic myelogenous leukemia cells as a highly phosphorylated substrate for the chimeric p210(bcr-abl) protein, DOK1 was suspected to play a role in leukemogenesis. 16823827 2006
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.300 Biomarker group CTD_human Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and Dok3 as lung tumor suppressors. 20139980 2010
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.300 Biomarker disease CTD_human Identification of DOK genes as lung tumor suppressors. 20139980 2010